Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Clin Cancer Res. 2018 Dec 18;25(7):2278–2289. doi: 10.1158/1078-0432.CCR-18-2728

Figure 2. Prexasertib is active as a single agent in preclinical models of pediatric soft tissue tumors.

Figure 2.

The best response achieved with prexasertib monotherapy was determined by averaging the responses of individual mice in each model (n ≥ 4 mice/arm) and is indicated above (%ΔT/C) or below (%regression) each bar. Gray shading indicates stable disease. aRMS: alveolar rhabdomyosarcoma; eRMS: embryonal rhabdomyosarcoma; DSRCT: desmoplastic small round cell tumor; MRT: malignant rhabdoid tumor; NB: neuroblastoma; Other: hepatoblastoma (CTG-1072), retinoblastoma (Y79). * denotes neuroblastoma models that were previously published in (10) Lowery CD, et al. Clin Cancer Res 2017;23(15):4354–63.